LA-Med study shows broad media mix among specialists
The LA-Med Specialist Physician Study 2026 shows continued strong use of journals, alongside congresses, web research and AI tools.
Laila/Adobe Stock
Valerio Therapeutics signs agreement to acquire Etherna
Valerio Therapeutics plans to acquire Etherna at a €30 million enterprise value and funds the deal with a €40.25 million PIPE financing.
Daiichi Sankyo names Markus Kosch head of Europe business
Daiichi Sankyo appoints Markus Kosch to lead its European business from April 2027 and combines Oncology and Specialty in a new structure.
BioMarin to acquire Alesta for HPP candidate ALE1
BioMarin will acquire Alesta Therapeutics to add ALE1, an oral Phase 1/2a candidate for hypophosphatasia, to its pipeline.
Moderna reports positive Phase 3 melanoma data
Moderna reported positive Phase 3 topline data for intismeran autogene plus pembrolizumab in adjuvant melanoma treatment.
NIM study: Longevity has yet to become an everyday priority
A NIM survey in five countries finds limited everyday adoption of longevity, while younger consumers show openness to new offers.
Johnson & Johnson publishes report on surgical intelligence
Johnson & Johnson’s new report outlines how connected data, AI and governance could shape the next stage of digital surgery.
Snapchat adds multi-CTA ad format for pharma disclosure needs
Snapchat is adding a pharma ad format with up to three disclaimer CTAs for safety, patient and prescribing information in one unit.
NAD recommends changes to Sanofi Dupixent advertising
After Galderma’s challenge, NAD advised Sanofi to change selected Dupixent advertising claims on clearer skin and itch relief.
Quanterix appoints Jim Gute as Chief Commercial Officer
Quanterix has named Jim Gute Chief Commercial Officer, tasking him with leading commercial growth across biomarker testing and diagnostics.